[1] Parnetti L, Castrioto A, Chiasserini D, et al.Cerebrospinal fluid biomarkers in Parkinson disease[J]. Nat Rev Neurol,2013,9(3):131-140.
[2] Wang Y, Shi M, Chung KA, et al. Phosphorylated α-synuclein in Parkinson's disease[J]. Sci Transl Med,2012, 4(121):121ra20.
[3] Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, et al.α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study[J]. Lancet Neurol,2011,10(3):230-240.
[4] Malek N, Swallow D, Grosset KA, et al.Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease-a systematic review[J]. Acta Neurol Scand,2014,130(2):59-72.
[5] Hong Z, Shi M, Chung KA, et al.DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease[J]. Brain,2010,133(Pt 3):713-726.
[6] Ding J, Zhang J, Wang X, et al.Relationship between the plasma levels of neurodegenerative proteins and motor subtypes of Parkinson's disease[J]. J Neural Transm (Vienna),2017,124(3):353-360.
[7] Shi M, Zabetian CP, Hancock AM, et al.Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease[J]. Neurosci Lett,2010,480(1):78-82.
[8] Devic I, Hwang H, Edgar JS, et al.Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease[J]. Brain,2011,134(Pt 7):e178.
[9] Foulds PG, Mitchell JD, Parker A, et al.Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease[J]. FASEB J,2011,25(12):4127-4137.
[10] Shahnawaz M, Tokuda T, Waragai M, et al.Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal Fluid[J]. JAMA Neurol,2017,74(2):163-172.
[11] Waragai M, Wei J, Fujita M, et al.Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's di-sease[J]. Biochem Biophys Res Commun,2006,345(3):967-972.
[12] Kang WY, Yang Q, Jiang XF, et al.Salivary DJ-1 could be an indicator of Parkinson's disease progression[J]. Front Aging Neurosci,2014,6:102.
[13] LeWitt P, Schultz L, Auinger P, et al. CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease[J]. Brain Res,2011,1408:88-97.
[14] Goldstein DS, Holmes C, Sullivan P, et al.Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies[J]. Parkinsonism Relat Disord,2016,31:79-86.
[15] Bogdanov M, Matson WR, Wang L, et al.Metabolomic profiling to develop blood biomarkers for Parkinson's di-sease[J]. Brain,2008,131(Pt 2):389-396.
[16] Seet RC, Lee CY, Lim EC, et al.Oxidative damage in Parkinson disease: Measurement using accurate biomar-kers[J]. Free Radic Biol Med,2010,48(4):560-566.
[17] Sohmiya M, Tanaka M, Tak NW, et al.Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease[J]. J Neurol Sci,2004, 223(2):161-166.
[18] Isobe C, Abe T, Terayama Y.Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2'-deoxyguanosine in the CSF of patients with Alzheimer's disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process[J]. J Neurol,2010,257(3):399-404.
[19] Trezzi JP, Galozzi S, Jaeger C, et al.Distinct metabolo-mic signature in cerebrospinal fluid in early parkinson's disease[J]. Mov Disord,2017,32(10):1401-1408.
[20] Luan H, Liu LF, Tang Z, et al.Comprehensive urinary metabolomic profiling and identification of potential noninvasive marker for idiopathic Parkinson's disease[J]. Sci Rep,2015,5:13888.
[21] Luan H, Liu LF, Tang Z, et al.Elevated excretion of biopyrrin as a new marker for idiopathic Parkinson's di-sease[J]. Parkinsonism Relat Disord,2015,21(11):1371-1372.
[22] Brody DM, Litvan I, Warner S, et al.Relationship between uric acid levels and progressive supranuclear palsy[J]. Mov Disord,2016,31(5):663-667.
[23] Kasai T, Tokuda T, Ohmichi T, et al.Serum Levels of Coenzyme Q10 in Patients with Multiple System Atrophy[J]. PLoS One,2016,11(1):e0147574.
[24] Constantinescu R, Rosengren L, Johnels B, et al.Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders[J]. Parkinsonism Relat Disord,2010,16(2):142-145.
[25] Hansson O, Janelidze S, Hall S, et al.Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder[J]. Neurology,2017,88(10):930-937.
[26] Fairfoul G, McGuire LI, Pal S, et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies[J]. Ann Clin Transl Neurol,2016,3(10):812-818.
[27] Wang Y, Hancock AM, Bradner J, et al.Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy[J]. Am J Pathol,2011,178(4):1509-1516.
[28] Shi M, Bradner J, Hancock AM, et al.Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression[J]. Ann Neurol,2011,69(3):570-580.
[29] Hall S, Surova Y, Öhrfelt A, et al.CSF biomarkers and clinical progression of Parkinson disease[J]. Neurology,2015,84(1):57-63.
[30] Compta Y, Martí MJ, Ibarretxe-Bilbao N, et al.Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease[J]. Mov Disord,2009,24(15):2203-2210.
[31] Hall S, Surova Y, Öhrfelt A, et al.Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease[J]. Mov Disord,2016,31(6):898-905.
[32] Stewart T, Liu C, Ginghina C, et al.Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disea-se progression in the DATATOP cohort[J]. Am J Pathol,2014,184(4):966-975.
[33] Majbour NK, Vaikath NN, Eusebi P, et al.Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression[J]. Mov Disord,2016,31(10):1535-1542.
[34] Zuo LJ, Yu SY, Wang F, et al.Parkinson's Disease with Fatigue: Clinical Characteristics and Potential Mechanisms Relevant to α-Synuclein Oligomer[J]. J Clin Neurol,2016,12(2):172-180.
[35] Hu Y, Yu SY, Zuo LJ, et al.Parkinson disease with REM sleep behavior disorder: features, α-synuclein, and inflammation[J]. Neurology,2015,84(9):888-894.
[36] Cipriani S, Chen X, Schwarzschild MA.Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis[J]. Biomark Med,2010,4(5):701-712.
[37] Annanmaki T, Pessala-Driver A, Hokkanen L, et al.Uric acid associates with cognition in Parkinson's disease[J]. Parkinsonism Relat Disord, 2008,14(7):576-578.
[38] Moccia M, Picillo M, Erro R, et al.Presence and progression of non-motor symptoms in relation to uric acid in de novo Parkinson's disease[J]. Eur J Neurol,2015,22(1):93-98.
[39] Picillo M, Santangelo G, Moccia M, et al.Serum uric acid is associated with apathy in early, drug-naïve Parkinson's disease[J]. J Neural Transm (Vienna),2016, 123(4):371-377.
[40] Hirayama M, Nakamura T, Watanabe H, et al.Urinary 8-hydroxydeoxyguanosine correlate with hallucinations rather than motor symptoms in Parkinson's disease[J]. Parkinsonism Relat Disord,2011,17(1):46-49.
[41] Dufek M, Hamanová M, Lokaj J, et al.Serum inflammatory biomarkers in Parkinson's disease[J]. Parkinsonism Relat Disord,2009,15(4):318-320.
[42] Eidson LN, Kannarkat GT, Barnum CJ, et al.Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of di-sease severity in subjects with Parkinson's disease[J]. J Neuroinflammation,2017,14(1):164.
[43] Rentzos M, Nikolaou C, Andreadou E, et al.Circulating interleukin-15 and RANTES chemokine in Parkinson's disease[J]. Acta Neurol Scand,2007,116(6):374-379.
[44] Chen S, Liu Y, Niu Y, et al.Increased abundance of myeloid-derived suppressor cells and Th17 cells in peripheral blood of newly-diagnosed Parkinson's disease patients[J]. Neurosci Lett,2017,648:21-25.
[45] Chen Y, Yu M, Liu X, et al.Clinical characteristics and peripheral T cell subsets in Parkinson's disease patients with constipation[J]. Int J Clin Exp Pathol,2015,8(3):2495-504.
[46] Wang Y, Liu H, Du XD, et al.Association of low serum BDNF with depression in patients with Parkinson's di-sease[J]. Parkinsonism Relat Disord,2017,41:73-78.
[47] Ma J, Jiang Q, Xu J, et al.Plasma insulin-like growth factor 1 is associated with cognitive impairment in Parkinson's disease[J]. Dement Geriatr Cogn Disord,2015, 39(5-6):251-256.
[48] Lim NS, Swanson CR, Cherng HR, et al.Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease[J]. Ann Clin Transl Neurol,2016,3(5):346-355.
[49] Jiang QW, Wang C, Zhou Y, et al.Plasma epidermal growth factor decreased in the early stage of Parkinson's disease[J]. Aging Dis,2015,6(3):168-173.
[50] Parnetti L, Chiasserini D, Bellomo G, et al.Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias[J]. Mov Disord,2011,26(8):1428-1435.
[51] Parnetti L, Farotti L, Eusebi P, et al.Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease[J]. Front Aging Neurosci,2014,6:53.
[52] Delgado-Alvarado M, Gago B, Gorostidi A, et al.Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study[J]. Mov Disord,2017,32(7):1066-1073.
[53] Magdalinou NK, Paterson RW, Schott JM, et al.A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes[J]. J Neurol Neurosurg Psychiatry,2015,86(11):1240-1247.
[54] Herbert MK, Eeftens JM, Aerts MB, et al.CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls[J]. Parkinsonism Relat Disord,2014,20(1):112-115.
[55] Bäckström DC, Eriksson Domellöf M, Linder J, et al.Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease[J]. JAMA Neurol,2015,72(10):1175-1182.
[56] Mollenhauer B, Caspell-Garcia CJ, Coffey CS, et al.Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls[J]. Neurology,2017,89(19):1959-1969.
[57] Mollenhauer B, Batrla R, El-Agnaf O, et al.A user's guide for α-synuclein biomarker studies in biological flui-ds: Perianalytical considerations[J]. Mov Disord,2017, 32(8):1117-1130.
